LATEST NEWS :
Mentorship Program For UPSC and UPPCS separate Batch in English & Hindi . Limited seats available . For more details kindly give us a call on 7388114444 , 7355556256.
asdas
Print Friendly and PDF

Nafithromycin

25.11.2024

 

Nafithromycin

 

For Prelims: About Nafithromycin, Key facts about Community-Acquired Bacterial Pneumonia

 

Why in the news?   

           In a ground breaking step for India’s biotechnology sector, the Union Minister formally launched the first indigenous antibiotic "Nafithromycin" for resistant infections.

 

About Nafithromycin:

  • It is an antibiotic which has been developed with the support of "Biotechnology Industry Research Assistance Council" (BIRAC).
  • It has been brought to market under the trade name "Miqnaf".
  • It is the country's first indigenously developed antibiotic aimed at tackling Antimicrobial Resistance (AMR).
  • This innovation is designed to treat Community-Acquired Bacterial Pneumonia (CABP).
  • Nafithromycin’s efficacy stands out as it targets both typical and atypical pathogens, offering a potent solution where no new antibiotic in this class has been developed worldwide for over three decades.
  • The antibiotic has minimal gastrointestinal side effects, no significant drug interactions, and remains unaffected by food, making it a versatile option for patients.
  • It offers 10x Efficacy with Just 3 doses to Combat Drug-Resistant Pneumonia.
  • The development of Nafithromycin represents 14 years of dedicated research and an investment of ₹500 crores, with clinical trials spanning the U.S., Europe, and India.

Key facts about Community-Acquired Bacterial Pneumonia:

  • It is one of the most common infectious diseases and an important cause of mortality and morbidity worldwide.
  • Typical bacterial pathogens that cause CAP include Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.

                                                                Source: PIB

 

Consider the following statements regarding the Nafithromycin:

1)It is an antibiotic which has been developed with the support of "Biotechnology Industry Research Assistance Council" (BIRAC).

2)It has been brought to market under the trade name "Miqnaf".

3)It is the country's Second indigenously developed antibiotic aimed at tackling Antimicrobial Resistance (AMR).

 

How many of the above statements are correct?

A.Only one

B.Only two

C.All three

D.None

 

Answer B

Get a Callback